Dual orexin receptor antagonist in treatment of insomnia
Sažetak
Dvojni antagonisti oreksinskih receptora su nova grupa lekova koja se nametnula kao kompetentna zamena za hipnotike izbora. Oni imaju relativno retka neželjena dejstva koja se u većini slučajeva dobro podnose, i to u prvenstveno u obliku rezidualne pospanosti, umora i noćnih mora/uznemiravajućih snova. Prednost u odnosnu na konvencionalne hipnotike proizilazi iz specifičnosti njihovih ciljnih receptora, i ogleda se kroz odsustvo stvarnja tolerancije posle dugotrajne upotrebe, kao i ktoz povoljan sigurnosni profil. Ovi lekovi se posebno nameću u nekim od posebnih grupa pacijenata, kao što su starije osobe. Trenutna i buduća istraživanja su orijentisana ka proučavanju njihovog uticaja na pojedinačne grupe oboljenja, kao što su bolesti zavisnosti i psihijatrijski poremećaji, demencije, stanja vezana za menopauzu i poremećaji cirkadijalnog ritma, između ostalih.
Reference
(1) Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.
(2) Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470. PMID: 27998379; PMCID: PMC5263087.
(3) Matheson E, Hainer BL. Insomnia: Pharmacologic Therapy. Am Fam Physician. 2017 Jul 1;96(1):29-35. PMID: 28671376.
(4) Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (February 1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell.92(4): 573–85. doi:10.1016/S0092-8674(00)80949-6. PMID: 9491897
(5) de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):322-7. doi: 10.1073/pnas.95.1.322. PMID: 9419374
(6) Marcus JN, Elmquist JK (2006). "Chapter 3. Orexin Projections and Localization of Orexin Receptors". In Nishino S, Sakurai T (eds.). The Orexin/Hypocretin System: Physiology and Pathophysiology. Springer. Pp 21-43 ISBN 9781592599509.
(7) Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28. PMID: 23197752.
(8) Kishi T, Matsunaga S, Iwata N. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS One. 2015 Aug 28;10(8):e0136910. doi: 10.1371/journal.pone.0136910. PMID: 26317363; PMCID: PMC4552781.
(9) Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev. 2017 Oct;35:1-7. doi: 10.1016/j.smrv.2016.09.004. Epub 2016 Oct 28. PMID: 28365447.
(10) Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2019 Dec 2;2(12):e1918254. doi: 10.1001/jamanetworkopen.2019.18254. PMID: 31880796; PMCID: PMC6991236.
(11) Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386. PMID: 23372274; PMCID: PMC3542986.
(12) Struyk A, Gargano C, Drexel M, Stoch SA, Svetnik V, Ma J, Mayleben D. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. Eur Neuropsychopharmacol. 2016 Oct;26(10):1649-56. doi: 10.1016/j.euroneuro.2016.07.002. Epub 2016 Aug 20. PMID: 27554636.
(13) Borchert JS, Wang B, Ramzanali M, Stein AB, Malaiyandi LM, Dineley KE. Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study. J Med Internet Res. 2019 Nov 8;21(11):e13371. doi: 10.2196/13371. PMID: 31702558; PMCID: PMC6874799.
(14) Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. J Clin Psychopharmacol. 2016 Aug;36(4):314-23. doi: 10.1097/JCP.0000000000000516. PMID: 27253658.
(15) Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020 Sep 14;43(9):zsaa123. doi: 10.1093/sleep/zsaa123. PMID: 32585700; PMCID: PMC7487867.
(16) Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020 Sep 9. doi: 10.1080/17425255.2020.1817380. Epub ahead of print. PMID: 32901578.
(17) Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology (Berl). 2016 Sep;233(18):3341-51. doi: 10.1007/s00213-016-4375-x. Epub 2016 Jul 16. PMID: 27424295; PMCID: PMC4989000.
(18) Trajanovic NN, Milovanovic SD. Upotreba hipnotika u rizičnim grupama pacijenata. Engrami. 2014, vol. 36, (1-2): 37-50. doi: 10.5937/engrami1402037T.
(19) Zeitzer JM, Joyce DS, McBean A, Quevedo YL, Hernandez B, Holty JE. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e206614. doi: 10.1001/jamanetworkopen.2020.6614. PMID: 32484552; PMCID: PMC7267849.
(20) Xu S, Cui Y, Shen J, Wang P. Suvorexant for the prevention of delirium: A meta-analysis. Medicine (Baltimore). 2020 Jul 24;99(30):e21043. doi: 10.1097/MD.0000000000021043. PMID: 32791676; PMCID: PMC7386982.
(21) Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020 Mar;16(3):541-551. doi: 10.1002/alz.12035. Epub 2020 Jan 15. PMID: 31944580.
(22) James MH, Aston-Jones G. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?". Brain Res. 2020 Mar 15;1731:146665. doi: 10.1016/j.brainres.2020.146665. Epub 2020 Jan 10. PMID: 31930996; PMCID: PMC7181304.
(23) Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology. 2020 May 15;168:108013. doi: 10.1016/j.neuropharm.2020.108013. Epub 2020 Feb 15. PMID: 32092435.
(24) Edmonds C, Swanoski M. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients. Consult Pharm. 2017 Mar 1;32(3):156-160. doi: 10.4140/TCP.n.2017.156. PMID: 28270270.
(25) Takeuchi Y, Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y. Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan. Curr Med Res Opin. 2020 Mar;36(3):465-471. doi: 10.1080/03007995.2019.1700361. Epub 2019 Dec 20. PMID: 31793350.
